<DOC>
	<DOC>NCT02369809</DOC>
	<brief_summary>Aim of the study is to gain more knowledge about efficacy and safety of Neovasculgen® in daily clinical practice and obtain information about the quality of life in patients treated with Neovasculgen®.</brief_summary>
	<brief_title>Non-Interventional Post Marketing Surveillance Study of Neovasculgen® in Patients With Chronic Lower Limb Ischemia</brief_title>
	<detailed_description>This is an open, controlled, prospective, comparative, multicentre study design. All patients received standard conservative therapy for chronic limb ischemia without cilostazol and prostaglandins and without surgical or endovascular vessel reconstruction. Surgical and endovascular vessel reconstruction was unsuitable for all of the patients</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Male or female person aged 40 or older Subject with diagnosed lower limb ischemia (FontainePokrovsky Stages IIaIII of chronic limb ischemia) Signed informed consent Any disease that can, in the opinion of the treating physician, affect the outcome of the study Patients with addictive disorders or substance abuse Pregnancy or nursing All other exclusion criteria listed in the summary of product characteristics (SmPC)</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Ischemia</keyword>
</DOC>